Microbion Corporation logo

Microbion Corporation

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serious diseases

16 employees · est. 2000 · Bozeman, United States

VS
Spero Therapeutics logo

Spero Therapeutics

Clinical-stage biotech company focused on rare diseases and diseases with high unmet need

44 employees · est. 2013 · Cambridge, United States

Microbion Corporation is the older company (2000 vs 2013).

Side-by-Side Comparison

Microbion Corporation Spero Therapeutics
Founded
2000 older 2013
Headquarters
Bozeman, United States Cambridge, United States
Employees
16 44
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Pharmaceutical
Funding Stage
Series Unknown IPO
Total Funding
Not tracked yet $374.60M
Funding Rounds
Not tracked yet 12
Services
Not tracked yet Development of Oral Carbapenem Antibiotics, Drug Pipeline for Rare and MDR Infections, Clinical Trial Execution, Partnership Development
Target Customers
Not tracked yet Patients with Complicated Urinary Tract Infections, Patients with Pyelonephritis, Healthcare Providers, Pharmaceutical Collaborators
Taxonomy
Pharmaceuticals, Therapeutics, Drug Development, Clinical-stage Biotechnology, Microbial Biofilm Prevention, Chronic Lung Diseases, Orthopedic Infections, Rare Disease Treatments, Antibiotic Resistance, Inhaled Drug Delivery, Topical Drug Development, Medical Device Coatings, Biofilm Prevention Technologies, Agricultural Biofilm Prevention, Industrial Biofilm Prevention Biopharmaceutical, Clinical-stage, Biotech Company, Bacterial Infections, Multi-drug Resistant, Rare Diseases, Oral Antimicrobial Agent, IV-administered Agent, Antibiotic, NTM Pulmonary Disease, Complicated Urinary Tract Infections, Business Development, Partnership Directed Programs, Drug Development, Commercialization
Website
microbioncorp.com sperotherapeutics.com
Microbion Corporation logo

About Microbion Corporation

Microbion Corporation is a clinical-stage pharmaceutical company focusing on developing therapeutic compounds for rare and serious diseases. The company's lead drug candidate, pravibismane, has received substantial support, totaling over $21 million in grants from the Cystic Fibrosis Foundation, NIH...

Spero Therapeutics logo

About Spero Therapeutics

Spero Therapeutics, founded in 2013 and headquartered in the United States, is a multi-asset, clinical-stage biotech company specializing in treatments for multidrug-resistant bacterial infections and rare diseases. With a strong focus on addressing antibiotic resistance, the company is carving out...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Microbion Corporation and Spero Therapeutics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Microbion Corporation and Spero Therapeutics — by email.

Frequently Asked Questions

Microbion Corporation — Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serious diseases . Spero Therapeutics — Clinical-stage biotech company focused on rare diseases and diseases with high unmet need. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Microbion Corporation has raised undisclosed funding while Spero Therapeutics has raised $374.60M.
Microbion Corporation and Spero Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Microbion Corporation with someone else

Start typing a company name or domain.

Related Comparisons

One analytics cookie (Google Analytics). Cookie Policy